Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
Cindy Howry, Executive Principal at Howry Solutions, shared a post on LinkedIn:
”FDA Approves First Treatment for Ataxia-Telangiectasia
The FDA has approved Aqneursa (levacetylleucine), an oral suspension that marks the first-ever treatment specifically approved for ataxia—a progressive neurological condition that affects movement and coordination—in patients with ataxia-telangiectasia.
The approval applies to adults and children weighing at least 15 kg (about 33 pounds).
This represents a significant milestone for a rare genetic disorder that has had no targeted treatment options until now.
Aqneursa builds on the medication’s prior FDA approval in 2024 for treating neurological symptoms in another rare genetic condition, Niemann-Pick disease type C.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 16:42Kate Grushetzkaya: The Essential Flow Cytometry Checklist – 6 Steps to Better Data
-
Sep 20, 2026, 16:32New Episode of The Hematologist Podcast – ASH
-
Sep 20, 2026, 16:26Thomas Schinecker: A New Era for Health Innovation – Inside the Roche Genentech Innovation Center
-
Sep 20, 2026, 16:19Astha Srivastava: The Missing Megakaryocytes in Amegakaryocytic Thrombocytopenia
-
Sep 20, 2026, 16:19Heghine Khachatryan: An Elegant Example of Precision Thrombolysis – Targeting the Scaffold of Microvascular Thrombosis
-
Sep 20, 2026, 16:01Mohamed Ismail: Managing Extensive Iliofemoral and Inferior Vena Cava DVT
-
Sep 20, 2026, 15:58Can αIIbβ3 Receptor Play a Role in Platelet Production – Glanzmann’s Research Foundation
-
Sep 20, 2026, 15:46Alexsander Santiago: Evaluating Clinical Harm from Missing versus Overdiagnosing HIT
-
Sep 20, 2026, 15:28Nico Gagelmann: iMTSS to Dissect the Drivers of Post-Transplant Outcomes